Raymond James raised the firm’s price target on BridgeBio to $46 from $29 and keeps an Outperform rating on the shares. The price target increase reflects the firm’s updated analysis of the top-line results from Part B of the ATTRibute-CM study evaluating acoramidis for the treatment of patients with transthyretin amyloid cardiomyopathy. The firm currently forecasts commercial launch of acoramidis during 4Q24 with ~$1B in peak sales globally during 2028, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BBIO:
- BridgeBio data in ATTR-CM ‘bodes well’ for Alnylam, says BofA
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio reports inducement grants under Nasdaq listing rule
- Intellia has positive read through from BridgeBio data, says BofA
- BridgeBio price target raised to $42 from $32 at BTIG